A phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, rivoceranib, for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC).

被引：0
|
作者：
Kang, Hyunseok
Ahn, Myung-Ju
Muzaffar, Jameel
Keam, Bhumsuk
Bowles, Daniel W.
Wong, Deborah J. L.
Ho, Alan Loh
Kim, Sung-Bae
Worden, Francis P.
Yun, Tak
Sari, Suha
Conlan, Maureen G.
Hanna, Glenn J.
机构：
[1] UCSF Helen Diller Family Comprehens Canc Ctr, Hematol Oncol, San Francisco, CA USA
[2] Sungkyunkwan Univ Sch Med, Samsung Med Ctr, Seoul, South Korea
[3] H Lee Moffitt Canc Ctr & Res Inst, Head & Neck & Endocrine Oncol, Tampa, FL USA
[4] Seoul Natl Univ Hosp, Seoul, South Korea
[5] Univ Colorado Canc Ctr, Div Med Oncol, Aurora, CO USA
[6] Univ Calif Los Angeles, Los Angeles, CA USA
[7] Mem Sloan Kettering Canc Ctr, Head & Neck Serv, Div Solid Tumor Oncol, New York, NY USA
[8] Univ Ulsan Coll Med, Asan Med Ctr, Seoul, South Korea
[9] Univ Michigan, Rogel Canc Ctr, Endocrine Oncol Clin, Ann Arbor, MI USA
[10] Natl Canc Ctr, Ctr Specif Organs Canc, Rare Cancers Clin, Goyang Si, Gyeonggi Do, South Korea
[11] Elevar Therapeut, Salt Lake City, UT USA
[12] Dana Farber Canc Inst, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6020
引用
收藏
页数：1
相关论文
共 50 条
  • [41] N-Glycosylation regulates ligand-dependent activation and signaling of vascular endothelial growth factor receptor 2 (VEGFR2)
    Chandler, Kevin Brown
    Leon, Deborah R.
    Kuang, Jenevieve
    Meyer, Rosana D.
    Rahimi, Nader
    Costello, Catherine E.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2019, 294 (35) : 13117 - 13130
  • [42] Results of ACCURACY: A phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut).
    Ferrarotto, Renata
    Metcalf, Robert
    Rodriguez, Cristina P.
    Muzaffar, Jameel
    Even, Caroline
    Perez, Augusto
    Herpen, Carla M. L. -Van
    Oliva, Marc
    Xia, Bing
    Bowles, Daniel W.
    Popovtzer, Aharon
    Winquist, Eric
    Wirth, Lori J.
    Hao, Desiree
    Kang, Hyunseok
    Hotte, Sebastien J.
    Stemmer, Salomon M.
    Mehra, Ranee
    Worden, Francis P.
    Ho, Alan Loh
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [43] Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma
    Keam, Bhumsuk
    Kim, Sung-Bae
    Shin, Seong Hoon
    Cho, Byoung Chul
    Lee, Keun-Wook
    Kim, Min Kyoung
    Yun, Hwan-Jung
    Lee, Se-Hoon
    Yoon, Dok Hyun
    Bang, Yung-Jue
    CANCER, 2015, 121 (15) : 2612 - 2617
  • [44] Morpholino-Mediated Isoform Modulation of Vascular Endothelial Growth Factor Receptor-2 (VEGFR2) Reduces Colon Cancer Xenograft Growth
    Stagg, Brian C.
    Uehara, Hironori
    Lambert, Nathan
    Rai, Ruju
    Gupta, Isha
    Radmall, Bryce
    Bates, Taylor
    Ambati, Balamurali K.
    CANCERS, 2014, 6 (04) : 2330 - 2342
  • [45] IS VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (VEGFR2) INVOLVED IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)? A COMBINED STRUCTURAL BIOLOGICAL AND GENETIC APPROACH
    Vazgiourakis, V.
    Zervou, M. I.
    Eliopoulos, E.
    Sharma, S.
    Sidiropoulos, P.
    Niewold, T.
    Boumpas, D. T.
    Goulielmos, G. N.
    ANNALS OF THE RHEUMATIC DISEASES, 2012, 71
  • [46] miR-219a suppresses human trophoblast cell invasion and proliferation by targeting vascular endothelial growth factor receptor 2 (VEGFR2)
    Guiju Zhou
    Zhifang Li
    Pin Hu
    Jing Wang
    Juanjuan Fu
    Bing Wei
    Yu Zhang
    Journal of Assisted Reproduction and Genetics, 2021, 38 : 461 - 470
  • [47] Identification of potential inhibitory peptide drugs for vascular endothelial growth factor receptor 2 (VEGFR2, KDR) using bacteria display methods
    Zhu, Y. M.
    Daugherty, P. S.
    2009 35TH ANNUAL NORTHEAST BIOENGINEERING CONFERENCE, 2009, : 183 - 184
  • [48] ACCURACY: phase (P) 2 trial of AL101, a pan-Notch inhibitor, in patients (pts) with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) with Notch activating mutations (Notchact mut).
    Ferrarotto, Renata
    Ho, Alan Loh
    Wirth, Lori J.
    Dekel, Edith
    Walker, Russell W.
    Vergara-Silva, Andrea Leninka
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [49] Carom, a novel protein induced by Homocysteine suppresses endothelial cell migration through inhibiting Vascular endothelial growth factor receptor 2 (VEGFR2) endocytosis
    Xia, Jixiang
    Xiong, Xinyu
    Saredy, Jason Jonathan
    Yang, Xiao-Feng
    Wang, Hong
    FASEB JOURNAL, 2019, 33
  • [50] miR-219a suppresses human trophoblast cell invasion and proliferation by targeting vascular endothelial growth factor receptor 2 (VEGFR2)
    Zhou, Guiju
    Li, Zhifang
    Hu, Pin
    Wang, Jing
    Fu, Juanjuan
    Wei, Bing
    Zhang, Yu
    JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, 2021, 38 (02) : 461 - 470
12345